Table 4.

Trials of daratumumab with bortezomib-based chemotherapy in newly diagnosed transplant-ineligible patients with myeloma

ALCYONE6 OCTANS17 VCDDLYRA19 
N 706 220 121 48 
Median age 71 y 69 y 75 y 66 y 
Age ≥75 y 30% 15% 50% 21% 
ECOG ≥2 25% 17% 18% 8% 
ISS stage     
Stage I 19% 25% 19% 33% 
Stage II 42% 44% 46% 33% 
Stage III 38% 30% 27% 33% 
High-risk FISH 16% 22% 16% 43% 
eGFR <30 mL/min Excluded 0.50% 4% Not stated 
ALCYONE6 OCTANS17 VCDDLYRA19 
N 706 220 121 48 
Median age 71 y 69 y 75 y 66 y 
Age ≥75 y 30% 15% 50% 21% 
ECOG ≥2 25% 17% 18% 8% 
ISS stage     
Stage I 19% 25% 19% 33% 
Stage II 42% 44% 46% 33% 
Stage III 38% 30% 27% 33% 
High-risk FISH 16% 22% 16% 43% 
eGFR <30 mL/min Excluded 0.50% 4% Not stated 
TherapyVMPDara + VMPVMPDara + VMPVCDVCDDVCDD
Response        
ORR 74% 91% 78% 88% 65% 75% 83% 
≥VGPR 50% 71% 43% 74% 32% 52% 70% 
MRD-negative 6% 22% 7% 30% 5% 16% Not stated 
Median PFS 19.3 m 36.4 m 18.2 m >18.2 m 18.9 m 25.8 m >36 m 
TherapyVMPDara + VMPVMPDara + VMPVCDVCDDVCDD
Response        
ORR 74% 91% 78% 88% 65% 75% 83% 
≥VGPR 50% 71% 43% 74% 32% 52% 70% 
MRD-negative 6% 22% 7% 30% 5% 16% Not stated 
Median PFS 19.3 m 36.4 m 18.2 m >18.2 m 18.9 m 25.8 m >36 m 

Dara + VMP, daratumumab and VMP; FISH, fluorescent in-situ hybridization cytogenetics; ORR, overall response rate.

View Large
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal